Compare NNVC & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | TELA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 31.4M |
| IPO Year | 2008 | 2019 |
| Metric | NNVC | TELA |
|---|---|---|
| Price | $1.43 | $0.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.00 | $1.90 |
| AVG Volume (30 Days) | ★ 157.6K | 94.4K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.92 | ★ 37.59 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.85 | $0.50 |
| 52 Week High | $1.93 | $1.50 |
| Indicator | NNVC | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 40.92 |
| Support Level | $1.23 | $0.61 |
| Resistance Level | $1.49 | $0.97 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 59.26 | 19.74 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.